Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Upgrade: Dedicated Screeners for Stocks & ETFs

Marker Therapeutics

Contributing Author

Recent Articles by Marker Therapeutics

Oct-19	Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer MRKR +15.38% GlobeNewswire
Sep-22	Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies MRKR GlobeNewswire
Mar-18	Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results MRKR GlobeNewswire
Feb-18	Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference MRKR GlobeNewswire
Jan-26	Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology MRKR -10.95% GlobeNewswire
Jan-05	Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer MRKR +16.23% GlobeNewswire
Nov-14	Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates MRKR GlobeNewswire
Nov-05	Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors MRKR GlobeNewswire
Nov-03	Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting MRKR GlobeNewswire
Oct-06	Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program MRKR +13.10% GlobeNewswire
Aug-28	Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference MRKR GlobeNewswire
Aug-26	Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma MRKR -20.63% GlobeNewswire
Jul-30	Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference MRKR GlobeNewswire
Jun-17	Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma MRKR GlobeNewswire
May-20	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma MRKR GlobeNewswire
May-19	Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies MRKR GlobeNewswire

Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)